17,261 trials
Metastatic Breast Cancer
Primary: Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) — 66.7; 40.6 Percentage of patients
Advanced Breast Cancer
Primary: Estimation of the Proportion of Progression-free Patients at 16 Wks. — 0 percentage of participants
Multiple Myeloma
Primary: Overall Survival — .64 proportion surviving at 4 years
Acute Myelogenous Leukemia · Myelodysplastic Syndromes · Chronic Myelogenous Leukemia
Primary: Response Rate (Complete Response [CR] Plus Partial Response [PR]) of Clofarabine Plus Cytarabine in Patients With Relapsed/Refractory AML, Untreated MDS, CML in Blast…
Breast Cancer
Primary: Percentage of Participants Who Achieved an Objective Confirmed Complete or Partial Overall Response — 62.5 Percentage of participants
Prostate Cancer
Primary: Progression-free Survival — 13 months
Subarachnoid Hemorrhage
Primary: Mean Plasma Nitrite Concentration (Micromol/L) — 4.2; 4.3; 2.6 micromol/L
Temporomandibular Joint Disorders · Orofacial Pain
Primary: Visual Analogic Scale for Pain Intensity (0-10) — 6.52; 4.8; .81; 2.05 units on a scale
Pancreatic Cancer
Primary: Overall Survival — 24.8 Months
Stress · Anxiety
Primary: Students Stress Levels — 75.62; 67.72; 72.45 units on a scale — p=0.006
Dyslipidemia · HIV Infections
Primary: LDL Cholesterol — 116.34; 118.84 mg/dl
Nasolabial Folds
Primary: Difference in Wrinkle Assessment Score, Between Pre-treatment and 12 Weeks Post-treatment. — 1.13 units on a scale
Hepatitis C
Primary: Change From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Day 15 — 5.83; 6.16; 5.88; -0.77 log 10 IU/mL
Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal Neoplasms
Primary: The Primary Efficacy End Point is the Number of Patients With an Objective Response. — 39 Participants — p=0.05
Acne Vulgaris
Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants